Pre-Renal vs Intrinsic AKI

Acute kidney injury is defined by a rise in serum creatinine, a fall in urine output, or both — but the creatinine and the urine output do not tell you why. AKI is a finding. The clinical work is determining the mechanism.

The traditional framework divides AKI into pre-renal, intrinsic renal, and post-renal causes. Post-renal AKI — obstruction — is excluded first with a bladder scan or renal ultrasound. The more common and clinically nuanced distinction is between pre-renal and intrinsic renal injury.

Pre-renal AKI is underperfusion. The kidneys are structurally intact but not receiving adequate blood flow. The tubules are functioning normally — they are avidly reabsorbing sodium and water in response to perceived volume depletion. Intrinsic AKI is structural injury to the kidney itself — most commonly acute tubular necrosis (ATN) from ischemia or nephrotoxins, but also glomerulonephritis, acute interstitial nephritis, and vascular causes.

Before ordering urine studies, assess volume status. The clinical examination is the most important first step — and it is frequently skipped in favor of laboratory reflexes.

Signs of volume depletion include dry mucous membranes, decreased skin turgor, tachycardia, orthostatic hypotension, flat neck veins, and decreased urine output. In the hospitalized patient, review the fluid balance, weight trend, and medication list. A patient who has been receiving aggressive diuresis, has had significant GI losses, or has poor oral intake is at high risk for pre-renal AKI.

Signs of volume overload — elevated JVP, pulmonary crackles, peripheral edema, S3 gallop — suggest a different mechanism. In heart failure and cirrhosis, the effective arterial blood volume is reduced despite total body fluid excess. These patients can develop pre-renal physiology even when they appear volume overloaded.

The clinical assessment of volume status guides the interpretation of every urine study that follows. A FeNa of 0.4% in a clinically volume-depleted patient is pre-renal. The same FeNa in a patient who is euvolemic and on diuretics requires a different interpretation.

Urine studies help distinguish pre-renal from intrinsic AKI by assessing tubular function. In pre-renal AKI, the tubules are intact and functioning — they conserve sodium and concentrate urine. In intrinsic AKI (particularly ATN), tubular function is impaired — sodium conservation is lost and concentrating ability is reduced.

The fractional excretion of sodium (FeNa) is calculated as: (urine Na × plasma Cr) / (plasma Na × urine Cr) × 100. A FeNa <1% suggests pre-renal physiology — the kidney is avidly reabsorbing sodium. A FeNa >2% suggests intrinsic renal injury with impaired tubular sodium reabsorption.

The critical limitation of FeNa is diuretics. Loop diuretics force sodium excretion regardless of volume status — a volume-depleted patient on furosemide will have a FeNa >1% despite pre-renal physiology. In diuretic-treated patients, the fractional excretion of urea (FeUrea) is more reliable. FeUrea <35% suggests pre-renal; FeUrea >50% suggests intrinsic injury. Urea reabsorption is less affected by loop diuretics.

Urine osmolality reflects concentrating ability. In pre-renal AKI, the kidney concentrates urine maximally — osmolality >500 mOsm/kg. In ATN, concentrating ability is impaired — osmolality is typically <350 mOsm/kg, often isosthenuric (similar to plasma, ~300 mOsm/kg).

Urine microscopy is the most specific test for intrinsic AKI — and the most underutilized. A fresh urine specimen examined within 30–60 minutes of collection provides diagnostic information that no other test can replicate.

In pre-renal AKI, the urine sediment is bland. Hyaline casts — formed from Tamm-Horsfall protein in concentrated urine — may be present, but they are non-specific and can be seen in normal urine.

In acute tubular necrosis, the hallmark finding is muddy brown granular casts — tubular epithelial cells and cellular debris that have sloughed into the tubular lumen. These are pathognomonic for ATN when present in the appropriate clinical context.

RBC casts indicate glomerular injury — red blood cells entering the tubular lumen through a damaged glomerular basement membrane. This finding points toward glomerulonephritis and warrants urgent nephrology consultation. WBC casts suggest acute interstitial nephritis (AIN) — often from a medication reaction (NSAIDs, antibiotics, PPIs) or infection. Waxy casts and broad casts indicate chronic, advanced renal disease.

A fluid challenge — administering isotonic crystalloid and observing the response in creatinine and urine output — can help confirm pre-renal physiology. Improvement in urine output and a falling creatinine after volume resuscitation supports the diagnosis.

The fluid challenge has important limits. It should not be used empirically in patients who are already volume overloaded, have heart failure, or have ARDS. In these patients, the clinical assessment of volume status must precede the decision to challenge — and a fluid challenge that worsens pulmonary edema or respiratory status is not a diagnostic maneuver, it is a clinical error.

In patients with hepatorenal syndrome — pre-renal physiology from splanchnic vasodilation and reduced effective arterial blood volume in cirrhosis — the creatinine may not improve with standard fluid resuscitation because the underlying mechanism is not simple volume depletion. Albumin infusion and vasoconstrictors (terlipressin, norepinephrine) are the appropriate interventions.

The creatinine in established ATN often continues to rise for 24–48 hours after the precipitating insult is removed — because tubular cells take time to die and the injury has already occurred. A creatinine that keeps climbing despite adequate resuscitation does not necessarily mean the resuscitation is failing; it may reflect the natural history of established ATN.

The cornerstone of pre-renal AKI management is restoring effective circulating volume. Isotonic crystalloid (normal saline or lactated Ringer's) is the standard resuscitation fluid. The rate and volume depend on the degree of volume depletion and the patient's ability to tolerate fluid — patients with heart failure or pulmonary edema require careful titration.

Nephrotoxin review is mandatory in every AKI. Hold NSAIDs, which reduce afferent arteriolar dilation and worsen renal perfusion. Hold ACE inhibitors and ARBs in the acute setting — they reduce efferent arteriolar tone and can worsen GFR when renal perfusion is already compromised. Hold metformin to prevent lactic acidosis. Contrast-enhanced imaging should be deferred when possible until renal function stabilizes.

Medication dose adjustment is required for renally cleared drugs. Antibiotics (particularly aminoglycosides, vancomycin, and beta-lactams), anticoagulants, and electrolyte-affecting medications all require dose modification based on current GFR. Pharmacy consultation is appropriate for complex regimens.

Monitoring during AKI: daily creatinine and BUN, urine output (hourly in severe AKI), electrolytes (potassium, bicarbonate), and fluid balance. Hyperkalemia, metabolic acidosis, and volume overload are the acute complications that require active management.

Expected course: pre-renal AKI that is identified and treated early typically resolves within 24–72 hours of adequate resuscitation. ATN has a longer recovery — the oliguric phase may last days to weeks, followed by a polyuric phase as tubular function recovers. Full creatinine recovery may take weeks to months, and some patients do not return to baseline.

Escalation: nephrology consultation is appropriate for AKI requiring dialysis consideration (refractory hyperkalemia, severe metabolic acidosis, volume overload unresponsive to diuretics, uremic symptoms), AKI without a clear cause, or AKI in the setting of systemic disease (vasculitis, myeloma, rapidly progressive glomerulonephritis). Dialysis is a bridge — not a treatment for the underlying cause.